Available Until 5/15/2024

Infectious Diseases Self-Assessment Program (IDSAP) Book 2: Global Public Health Issues (Cert # L239234)

ACPE Numbers: Various – see listing below
Release Date: 11/15/2023
Expiration Dates: 05/15/2024
Activity Type: Application‐based
CE Credits: 17 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non‐member)

This course is intended for board certified pharmacists in need of BCIDP recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to 17 contact hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ACCP and ASHP and professional development program for BCIDP recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

The target audience for Infectious Diseases Self-Assessment Program (IDSAP) Book 2: Global Public Health Issues is board-certified infectious diseases pharmacists caring for adult or pediatric patients in the acute or ambulatory setting.

Board certified pharmacists are eligible to receive up to 17 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours 

Assessment Pass Point

Global Public Health Issues I


4.50 (ACPE/BPS)


Global Public Health Issues II


4.00 (ACPE/BPS)


Global Public Health Issues III


4.00 (ACPE/BPS)


Global Public Health Issues IV


4.50 (ACPE/BPS)


Global Public Health Issues I
ACPE #: 0217-9999-23-219-H01-P
Chapter: Malaria and Other Parasitic Infections

  • Evaluate patients with the following parasitic infections by microbiological features, clinical signs, and worldwide prevalence: malaria, cryptosporidiosis, cysticercosis, giardiasis, toxoplasmosis, amebiasis.
  • Distinguish the effect climate change will have on the epidemiology of common parasitic infections and how it affects the role of health care providers.
  • Design recommendations for pharmacologic and nonpharmacologic prophylaxis against parasitic infections.
  • Develop recommendations for patients who need prophylaxis or treatment for common parasitic infections without imposing bias or stigma. 

Chapter: Travel Medicine

  • Account for changes in pharmacotherapy due to evolution in the field of travel medicine.
  • Justify the role of the pharmacist in travel medicine.
  • Classify common types of infections associated with global travel.
  • Evaluate current resources for infectious diseases in travel medicine.
  • Design treatment regimen and consult for a patient (e.g., pre-travel, during travel, and post-travel).
  • Develop a plan for post-travel monitoring. 

Global Public Health Issues II
ACPE #:0217-9999-23-220-H01-P
Chapter: Tuberculosis and Resistance

  • Distinguish between the types of drug-resistant tuberculosis.
  • Evaluate differences in current guidelines of drug therapy recommendations for the management of drug-resistant tuberculosis.
  • Design an optimal treatment regimen for drug-resistant tuberculosis in different patient-specific clinical scenarios.
  • Develop a monitoring plan to assess medication effectiveness and toxicity in patients receiving treatment for drug-resistant tuberculosis 

Chapter: Antimicrobial Stewardship and Resistance in Low- and Middle-Income Countries

  • Design an antimicrobial stewardship program specific to a low- or middle-income country (LMIC).
  • Implement an antimicrobial stewardship program appropriate for an LMIC.
  • Evaluate strategies to combat antimicrobial resistance. 

Global Public Health Issues III
ACPE #: 0217-9999-23-221-H01-P
Chapter: HIV Response in Low- and Middle-Income Countries

  • Devise strategies to address inequalities in the management of HIV in low- and middle-income countries (LMIC).
  • Design a patient-centered plan for the management of HIV in adults in alignment with the WHO guidelines.
  • Distinguish differences in treatment and prevention guidelines for HIV in LMIC compared with high-income countries.
  • Develop a monitoring plan to assess the efficacy, safety, and adherence to antiretroviral therapy in patients with HIV in LMIC.
  • Evaluate long-acting injectables and investigational agents to determine their role in the treatment and prevention of HIV. 

Chapter: Health Equity in Infectious Diseases

  • Distinguish among the terms health equity and health disparities.
  • Evaluate the impact of health disparities on patient health outcomes.
  • Evaluate the association between social determinants of health and patient health outcomes.
  • Determine how health inequities affect the distribution of COVID-19.
  • Evaluate social risk factors that contribute to pharmacoequity.
  • Develop strategies to close the pharmacoequity gap. 

Global Public Health Issues IV
ACPE #: 0217-9999-23-222-H01-P
Interactive Case: Re-introduction of Anti-TB Therapy in Patients with Hepatic Toxicity

  • Estimate a patient’s risk of drug-induced hepatotoxicity.
  • Analyze anti-tuberculosis (TB) medications that can cause hepatotoxicity.
  • Construct a pharmacotherapeutic plan for a patient who is being reintroduced to a hepatotoxic anti-TB medication.
  • Assess potential challenges associated with anti-TB medications that cause hepatotoxicity and efficacy of care. 

Recorded Webcast: Drug Acquisition and Allocation in Resource-Limited Settings

  • Evaluate the functions of the WHO Essential Medicines List.
  • Assess the current state of essential medicines around the world, particularly in low- and middle-income countries (LMIC).
  • Analyze current areas of inefficiencies and how they affect patient care.
  • Justify recommendations on best practices and real-life examples to ensure availability, accountability, and affordability of medications.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, the American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Consultancies: Jeanine Abrons (Abrons Consulting LLC and Travel Medica; APhA; Editorial Boards – Pulses and Pharmacy Today); Elias B. Chahine (Seqirus, Gilead); Esther O. Fasanmi: (Theratechnologies); Bernadette Jakeman (Wolters Kluwer/ Lexicomp); Rakhi Karwa: (Abbott Fund [spouse/significant other]; Direct Relief [spouse/significant other]); Cynthia Nguyen (Roche Diagnostics); Sonak Pastakia (Abbott Fund; Direct Relief); Riley Williams II: (VPR on behalf of Sanofi)
  • Stock Ownership: Yardlee Kauffman (Astra Zeneca [spouse/significant other])
  • Royalties: Jeanine Abrons [spouse or significant other] (Abrons Airway Device)
  • Grants: Crystal Kay Hodge (NIMHD; HRSA; CDC through TBESC); Bernadette Jakeman (Merck); Madeline A. King (Wayne State); James Sanders (Merck; Shionogi): Veena Venugopalan (Merck)
  • Honoraria: Jeanine Abrons (PharmCon or Free CE – DEI Lectures); Elias B. Chahine (Seqirus); Madeline A. King (La Jolla/ Tetraphase; ContagionLive; Shionogi); Sheila Seed (Valneva); Riley Williams II (VPR on behalf of Sanofi)

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.


ACCP and ASHP collaborate on infectious diseases activities.